secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001213900-22-013743
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics promotes Mahal to COO, Heller to exit, new CMO role created
-------------------------------------------------------------------------------

- Jeet Mahal promoted to COO (retains CFO); salary raised to $445,000, bonus target 45%.
- Kevin Heller's employment ends May 17, 2022; consulting through March 2023 at ~$37,939/month plus COBRA.
- Wendy Pang promoted to SVP of Research and Translational Medicine, effective March 21, 2022.
- New Chief Medical Officer position created; active search underway. Judith Shizuru leads clinical interim.
- All changes effective March 21, 2022, except Heller's separation date May 17, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022013743/0001213900-22-013743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022013743/ea157147-8k_jasperthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-013743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer